Close Menu

Cequent Pharmaceuticals said this week that it has received notices that the European Patent Office and the Korean Intellectual Property Office intend to grant patents covering the company's core RNAi technology.

The patent applications, entitled "Compositions for Bacterial-Mediated Gene Silencing and Methods Using the Same," relate to Cequent's so-called transkingdom RNAi technology, which involves using attenuated Escherichia coli to transcribe therapeutic shRNAs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Apr
17
Sponsored by
Isoplexis

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.